Trial Profile
A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-Like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to less than 24 Month-Old Children and in 2 Month-Old Infants
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs MEDI 534 (Primary)
- Indications Parainfluenza virus infections; Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors MedImmune
- 21 Jul 2019 This trial has been completed in United Kigndom, according to the European Clinical Trials Database record.
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Sep 2011 Planned end date changed from 1 Jan 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.